Drugs / Aclacinomycin
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01690507 | Nov 2012 → May 2015 | acute myeloid leukemia, myelodysplastic syndrome | Chinese PLA General Hospital | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07512700 | Sep 2025 → Sep 2028 expected | acute monocytic leukemia | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07514936 | Nov 2024 → Sep 2027 expected | acute myeloid leukemia | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06928376 | Apr 2024 → Sep 2025 overdue | acute myeloid leukemia | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06084819 | Aug 2023 → Jan 2029 expected | acute myeloid leukemia | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06068621 | Mar 2023 → May 2024 | acute myeloid leukemia | Chinese PLA General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05662956 | Dec 2022 → Dec 2024 | acute myeloid leukemia | Hematology department of the 920th hospital | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05805072 | May 2023 → Jun 2024 | acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| — | NCT02432911 | Apr 2015 → May 2018 | acute myeloid leukemia | Jianxiang Wang | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05807347 Background | Feb 2023 → Feb 2024 | acute myeloid leukemia | Hematology department of the 920th hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02937662 Comparator | Oct 2016 → Apr 2020 | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05726110 Background | Jan 2023 → Dec 2024 overdue | acute myeloid leukemia | Shanxi Bethune Hospital | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03026842 Comparator | Jan 2017 → Dec 2023 | acute myeloid leukemia | The First Hospital of Jilin University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02432872 Background | Apr 2015 → May 2018 | acute myeloid leukemia | Jianxiang Wang | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aclacinomycin | “In the control arm, patients received other physician-directed regimen including fludarabine, cytarabine with/without granulocyte stimulating factor(FLA±G) regimen,cytarabine...” NCT02937662 ↗13“combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.” NCT02432872 ↗ “Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7;” NCT05662956 ↗ “Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7” NCT05807347 ↗ “3. Aclacinomycin (20 mg/day, days 1,3,5).” NCT07512700 ↗ |
| Route | Intravenous | “intravenously on days 3 to 6” NCT05805072 ↗ |